Study: Biotech no riskier for investors
Despite lower sales, lack of profits and heavy R&D spending, biotech companies that went public between 1997 and 2016 reached similar market caps as non-biotech companies, according to an academic study.
Bentley University
Gilead Covid-19 drug remdesivir benefited from $6.5B in NIH-funded basic research, study finds
Research on the drug’s molecular target dates back to the 1950s. A spokesperson for Gilead noted that the company anticipates potentially investing more than $1 billion on the drug this year alone.